Search
for
Sort by
Research 391–420 of 667
- Gender-Affirming Hormonal Treatment in Transgender People Assigned Female at Birth (AFAB)
- Cardiovascular Risks in Women with Polycystic Ovary Syndrome (PCOS): A Narrative Review
- Unique Circulating MicroRNA Signatures Distinguish Severe Alopecia Areata from Other Inflammatory Skin Diseases
- Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot study
- COVID‐19 and cutaneous manifestations: A review of the published literature
- Effectiveness of Low-dose Ethinylestradiol/Cyproterone Acetate and Ethinylestradiol/Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-blind, Triple-dummy Study.
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Progestogens with Antiandrogenic Properties
- The JAK/STAT signaling pathway: from bench to clinic
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Vaccines, adjuvants and autoimmunity
- Tissue engineering; strategies, tissues, and biomaterials
- COVID-19: Pulmonary and Extra Pulmonary Manifestations
- Recurrent implantation failure: A comprehensive summary from etiology to treatment
- Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies
- Long-COVID Clinical Features and Risk Factors: A Retrospective Analysis of Patients from the STOP-COVID Registry of the PoLoCOV Study
- Androgen insufficiency in women: diagnostic and therapeutic implications
- Vitamin D Concentrations are Decreased in Patients with Alopecia Areata
- Immune mechanisms associated with sex-based differences in severe COVID-19 clinical outcomes
- Engineered extracellular vesicles for tissue repair and regeneration
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets
- Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
- Gender Differences in Response to COVID-19 Infection and Vaccination
- British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021
- New and Consolidated Therapeutic Options for Pubertal Induction in Hypogonadism: In-depth Review of the Literature
- Consequences of Anabolic-Androgenic Steroid Abuse in Males; Sexual and Reproductive Perspective
- Commonalities Between COVID-19 and Radiation Injury
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center